---
schema_version: "secwatch.filing_event.v1"
accession: "0001425450-24-000010"
form_type: "8-K"
ticker: "KIDS"
cik: "0001425450"
company_name: "ORTHOPEDIATRICS CORP"
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:31:50.764826+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OrthoPediatrics FY 2023 revenue $148.7M (+22% YoY); guides FY 2024 rev $197-200M

## Summary
- FY 2023 net loss $21.0M ($0.92/share) vs net income $1.3M ($0.06) in 2022; adjusted EBITDA rose to $5.0M from $0.2M.
- Q4 2023 revenue $37.6M (+21% YoY); gross margin 71.0% vs 68.5%; U.S. revenue +24%, international +13%.
- FY 2024 revenue guidance $197-200M (+32-34%); adjusted EBITDA guidance $8-9M.
- Acquired Boston Orthotics & Prosthetics with $80M debt financing; post-close cash ~$60M.

## SEC filing metadata
- accession: 0001425450-24-000010
- form_type: 8-K
- ticker: KIDS
- cik: 0001425450
- company_name: ORTHOPEDIATRICS CORP
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000010/0001425450-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000010/kids-20240306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001425450-24-000010
- JSON: https://secwatch.observer/filing/0001425450-24-000010.json
- Plain text: https://secwatch.observer/filing/0001425450-24-000010.txt

## Key facts
- Earnings Releases
  ORTHOPEDIATRICS CORP reported the full year ended December 31, 2023 results: revenue $148.7 million. Guidance reaffirmed.
  - Period: the full year ended December 31, 2023
  - Revenue: $148.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Record full year 2023 revenue of $148.7 million increased 22% compared to prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000010/0001425450-24-000010-index.htm
- Earnings Releases
  ORTHOPEDIATRICS CORP reported the fourth quarter ended December 31, 2023 results: revenue $37.6 million. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $37.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Generated total revenue of $37.6 million for fourth quarter 2023, up 21% from $31.0 million in fourth quarter 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000010/0001425450-24-000010-index.htm
- Earnings Releases
  ORTHOPEDIATRICS CORP reported full year 2024 results: revenue $197.0 million to $200.0 million. Guidance reaffirmed.
  - Period: full year 2024
  - Revenue: $197.0 million to $200.0 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Reiterated full year 2024 revenue guidance to be in a range of $197.0 million to $200.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000010/0001425450-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.